SG11202105137RA - Application of chidamide in combination with r-chop, and drug combination - Google Patents

Application of chidamide in combination with r-chop, and drug combination

Info

Publication number
SG11202105137RA
SG11202105137RA SG11202105137RA SG11202105137RA SG11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA SG 11202105137R A SG11202105137R A SG 11202105137RA
Authority
SG
Singapore
Prior art keywords
combination
chidamide
chop
application
drug
Prior art date
Application number
SG11202105137RA
Other languages
English (en)
Inventor
Xianping Lu
Weili Zhao
Xin Fu
Pengpeng Xu
Ting Liu
Original Assignee
Shenzhen Chipscreen Biosciences Co Ltd
Rui Jin Hospital Affiliated To Shanghai Jiao Tong Univ School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Chipscreen Biosciences Co Ltd, Rui Jin Hospital Affiliated To Shanghai Jiao Tong Univ School Of Medicine filed Critical Shenzhen Chipscreen Biosciences Co Ltd
Publication of SG11202105137RA publication Critical patent/SG11202105137RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202105137RA 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination SG11202105137RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811394614 2018-11-20
PCT/CN2019/119170 WO2020103788A1 (fr) 2018-11-20 2019-11-18 Application du chidamide associé à r-chop et combinaison de médicaments

Publications (1)

Publication Number Publication Date
SG11202105137RA true SG11202105137RA (en) 2021-06-29

Family

ID=70741744

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105137RA SG11202105137RA (en) 2018-11-20 2019-11-18 Application of chidamide in combination with r-chop, and drug combination

Country Status (12)

Country Link
US (1) US20220016147A1 (fr)
EP (1) EP3884943A4 (fr)
JP (1) JP7489397B2 (fr)
KR (1) KR20210104059A (fr)
CN (2) CN117797149A (fr)
AU (1) AU2019385373A1 (fr)
BR (1) BR112021009627A2 (fr)
CA (1) CA3120207A1 (fr)
PH (1) PH12021551138A1 (fr)
SG (1) SG11202105137RA (fr)
TW (1) TWI768263B (fr)
WO (1) WO2020103788A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118161618A (zh) * 2020-06-18 2024-06-11 苏州亚盛药业有限公司 包含Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂的组合产品及其用途
CN112274509B (zh) * 2020-12-02 2022-04-26 四川大学华西医院 西达本胺联合bcl2抑制剂在双表达型b细胞淋巴瘤中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100924737B1 (ko) * 2003-08-26 2009-11-04 슬로안-케테링인스티튜트퍼캔서리서치 Hdac 억제제를 이용한 암의 치료 방법
CN101470112A (zh) * 2007-12-28 2009-07-01 上海交通大学医学院附属瑞金医院 弥漫性大b细胞淋巴瘤治疗指导和预后判断的分子标志物
TWI808055B (zh) * 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CA3031365A1 (fr) 2016-07-20 2018-01-25 The Trustees Of Columbia University In The City Of New York Activateurs d'histone acetyltransferase et compositions et utilisations associees
CN107157978B (zh) * 2017-05-24 2021-06-18 中国药科大学 治疗ebv+dlbcl和dlbcl的药物及组合物
CN108743947B (zh) * 2018-07-04 2020-12-15 复旦大学附属肿瘤医院 一种治疗b细胞淋巴瘤的药物组合物

Also Published As

Publication number Publication date
JP2022511126A (ja) 2022-01-28
CN117797149A (zh) 2024-04-02
US20220016147A1 (en) 2022-01-20
WO2020103788A1 (fr) 2020-05-28
TWI768263B (zh) 2022-06-21
CA3120207A1 (fr) 2020-05-28
CN111195249A (zh) 2020-05-26
PH12021551138A1 (en) 2022-02-21
EP3884943A4 (fr) 2022-07-06
TW202033194A (zh) 2020-09-16
JP7489397B2 (ja) 2024-05-23
CN111195249B (zh) 2023-11-28
EP3884943A1 (fr) 2021-09-29
AU2019385373A1 (en) 2021-06-24
KR20210104059A (ko) 2021-08-24
BR112021009627A2 (pt) 2021-08-10

Similar Documents

Publication Publication Date Title
IL284835A (en) Pharmaceutical combination containing TNO155 and ribociclib
IL279015A (en) Anti-interleukin-17A antibody, its pharmaceutical preparation and its use
SG11202003320SA (en) Dihydropyrimidine compounds and uses thereof in medicine
SG11202105173VA (en) Modified cell expressing therapeutic agent and uses thereof
SG11202001647UA (en) Conjugate of vegf-grab protein and drug, and use thereof
GB201604213D0 (en) Drug combination and its use in therapy
PT3615035T (pt) Utilização de 20-hidroxiecdisona e os seus derivados no tratamento de miopatias
IL273339A (en) Griseofulbin compound and its medical use
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
GB201820659D0 (en) Novel compostions and their use in therapy
IL282527A (en) 5-Azaindazole history and their use
PL3658122T3 (pl) Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan
DK3334760T3 (da) Antistofcysteiner med kappe og uden kappe, og deres anvendelse i antistof-lægemiddel-konjugering
EP3630124A4 (fr) Composition synthétique comprenant des oligosaccharides et son utilisation dans un traitement médical
SG11202105137RA (en) Application of chidamide in combination with r-chop, and drug combination
GB201709840D0 (en) Methods and medical uses
SG11202101435XA (en) ANTIBODY AGAINST IL-1ß, PHARMACEUTICAL COMPOSITION AND USE THEREOF
SG11202004529XA (en) Transformed human cell and use thereof
IL282526A (en) 5-Azaindazole history and their use
SG11201906132UA (en) Insoluble complex or solvate thereof, pharmaceutical composition and use thereof
EP3696178A4 (fr) Composé hétérocyclique et son application en médecine
EP3615064A4 (fr) Compositions cellulaires enrichies et utilisation thérapeutique
GB201519644D0 (en) Therapy and pharmaceutical composition
PL3212280T3 (pl) Dopasowanie szumu usznego u pacjentów z implantem ślimakowym (CI) i implantem słuchowym pnia mózgu (ABI)
SG11202103806VA (en) 4-pyrazin-2-ylmethyl-morpholine derivatives and the use thereof as medicament